3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
3
Status
Recruiting
3
Sponsor Class
INDUSTRY
3
Study Type
Interventional
3
Sponsor
Cancer Type
Gastrointestinal
3
Conditions
Esophageal Squamous Cell Carcinoma
3
Colorectal Neoplasms
3
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Leukemia, Biphenotypic, Acute
2
Esophageal Neoplasms
2
Burkitt Lymphoma
2
Adenocarcinoma Of Esophagus
2
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pancreatic Neoplasms
1
Interventions
Bevacizumab
56
Cetuximab
50
Fluorouracil
45
Leucovorin
39
Oxaliplatin
38
pembrolizumab
31
Specimen Handling
27
Irinotecan
25
Magnetic Resonance Spectroscopy
17
Biopsy
17
Nivolumab
15
HMPL-013
13
Folfox protocol
13
Capecitabine
13
Gemcitabine
12
Cisplatin
12
trifluridine tipiracil drug combination
11
Panitumumab
11
Carboplatin
11
Pemetrexed
9
IFL protocol
9
encorafenib
8
balstilimab
8
Standard of Care
8
Paclitaxel
8
Early Intervention, Educational
8
130-nm albumin-bound paclitaxel
8
fludarabine
7
atezolizumab
7
Educational Status
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Colorectal Neoplasms
×
Levoleucovorin
×
90 days
×
Clear all
NCT06662786
2026-06-05
OrigAMI-2
Janssen Research & Development, LLC
Phase 3
Recruiting
1,000 enrolled
NCT06750094
2026-06-05
OrigAMI-3
Janssen Research & Development, LLC
Phase 3
Recruiting
700 enrolled
NCT05253651
2026-06-04
MOUNTAINEER-03
Seagen Inc.
Phase 3
Recruiting
400 enrolled